143
FDA’s review of MDMA for PTSD highlights study bias and safety concerns
(arstechnica.com)
you are viewing a single comment's thread
view the rest of the comments
view the rest of the comments
this post was submitted on 01 Jun 2024
143 points (93.3% liked)
News
23276 readers
3928 users here now
Welcome to the News community!
Rules:
1. Be civil
Attack the argument, not the person. No racism/sexism/bigotry. Good faith argumentation only. This includes accusing another user of being a bot or paid actor. Trolling is uncivil and is grounds for removal and/or a community ban. Do not respond to rule-breaking content; report it and move on.
2. All posts should contain a source (url) that is as reliable and unbiased as possible and must only contain one link.
Obvious right or left wing sources will be removed at the mods discretion. We have an actively updated blocklist, which you can see here: https://lemmy.world/post/2246130 if you feel like any website is missing, contact the mods. Supporting links can be added in comments or posted seperately but not to the post body.
3. No bots, spam or self-promotion.
Only approved bots, which follow the guidelines for bots set by the instance, are allowed.
4. Post titles should be the same as the article used as source.
Posts which titles don’t match the source won’t be removed, but the autoMod will notify you, and if your title misrepresents the original article, the post will be deleted. If the site changed their headline, the bot might still contact you, just ignore it, we won’t delete your post.
5. Only recent news is allowed.
Posts must be news from the most recent 30 days.
6. All posts must be news articles.
No opinion pieces, Listicles, editorials or celebrity gossip is allowed. All posts will be judged on a case-by-case basis.
7. No duplicate posts.
If a source you used was already posted by someone else, the autoMod will leave a message. Please remove your post if the autoMod is correct. If the post that matches your post is very old, we refer you to rule 5.
8. Misinformation is prohibited.
Misinformation / propaganda is strictly prohibited. Any comment or post containing or linking to misinformation will be removed. If you feel that your post has been removed in error, credible sources must be provided.
9. No link shorteners.
The auto mod will contact you if a link shortener is detected, please delete your post if they are right.
10. Don't copy entire article in your post body
For copyright reasons, you are not allowed to copy an entire article into your post body. This is an instance wide rule, that is strictly enforced in this community.
founded 1 year ago
MODERATORS
Nah, that's not the issue (nor do I believe in magic bullets, but that's a different matter). See, the issue is that MDMA can't be patented. Anyone can make it so no one pharmacorp can have a 20 year monopoly
I said potential to help cure. I think MDMA assisted psychotherapy, in particular, has the potential to cure PTSD in a lot of people. Not everyone. But a lot.
And the patent issue on this has been solved by starting a non-profit pharmaceutical company and getting grants and donations to fund these trials. And then patenting the treatment protocols under a public trust corp I believe. I follow MAPS quite a bit, the non-profit that spear headed a lot of this.
I think what the other poster said about the FDA approving drugs with more cardiovascular issues than MDMA is true and points towards corporate bias in the panel (which most of us probably know is true).
Treating mental health with SSRIs etc. is a big business. Some of that panel probably stands to lose money if some of those repeat customers find a cure.
You sound like you'd be interested in David Healy's work. Check out Children of the Cure if you haven't already. That, as well as a plethora of other shady things I learned in university, are responsible for reorienting me toward public policy rather than becoming a practicing psychologist.
I found a TED talk with him I'm listening now. Thanks for the lead I hadn't heard of him before.
Usually first to market work generics enjoys a year of exclusivity. Usually other companies abandon our back burnera project they don't make to market first. There's still money to be made. Just not as much.
I think you don't quite understand the comment.
Current pharmaceuticals are usually a (life)long prescription. It's not like antibiotics, where you get a dose for a few days or weeks and you're done. Antidepressants have to be taken for years. Every day. That means revenue every day. It's a treatment, not a cure.
MDMA on the other hand is a (potential) cure. You take it a few times under supervision and that's it.
Problem is, this takes away customers from the former group. And that means, far less revenue from "traditional" psychopharmacology products. MDMA cannibalizes other drugs.